Grants and Contracts Details
Effective therapeutic drug monitoring of intravenous (IV) vancomycin therapy is essential to mitigate the risk of acute kidney injury (AKI), estimated to be as high as 43% in the general population, as well as improve efficacy and therapeutic success.1.8 In vitro and in vivo data of IV vancomycin suggests that an area under the curve to minimal inhibitory concentration ratio (AUC24:MIC) of .400-600 ensures bactericidal activity and mitigates the emergence of MRSA resistance as well as development of acute kidney injury (AKI).8-10 As it has become apparent that trough concentrations may fail to accurately predict AUC24, with a trough to AUC24 correlation of
|Effective start/end date||12/1/20 → 11/30/21|
- American College of Clinical Pharmacy Foundation: $4,995.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.